Immunogen, Inc.

NASDAQ:IMGN   2:39:20 PM EDT
5.38
-0.07 (-1.28%)
Regulatory, Earnings Announcements

Immunogen Announces Positive Top-Line Results From Pivotal Soraya Trial Of Mirvetuximab Soravtansine In Ovarian Cancer

Published: 11/30/2021 12:53 GMT
Immunogen, Inc. (IMGN) - Immunogen Announces Positive Top-line Results From Pivotal Soraya Trial of Mirvetuximab Soravtansine in Ovarian Cancer.
Immunogen Inc - Trial Met Primary Endpoint With Confirmed Objective Response Rate of 32.4%.
Immunogen Inc - Bla Submission on Track for Q1 of 2022.
Immunogen Inc- Trial Showed Continued Demonstration of Favorable Tolerability Profile.
Immunogen Inc - Expect to Generate Top-line Data From Our Confirmatory Mirasol Trial in Q3 of 2022 to Support Potential Full Approval of Mirvetuximab.
Revenue is expected to be $25.69 Million
Adjusted EPS is expected to be -$0.18

Next Quarter Revenue Guidance is expected to be $8.64 Million
Next Quarter EPS Guidance is expected to be -$0.23

More details on our Analysts Page.